The activist is pushing for a shake-up of the contract drug manufacturer’s board. Source link
The activist is pushing for a shake-up of the contract drug manufacturer’s board. Source link
On April 3, 2023, Barclays downgraded their outlook for Catalent (NYSE:CTLT) from Overweight to Equal-Weight . Analyst Price Forecast Suggests…